Gh Research PLC (GHRS) SEC Filings — 2025
28 SEC filings for Gh Research PLC (GHRS) in 2025.
Filings
- Gh Research PLC 6-K Filing — 6-K · Nov 24, 2025
- GH Research to Present at Stifel Healthcare Conference — 6-K · Nov 7, 2025
- Gh Research PLC 6-K Filing — 6-K · Nov 6, 2025
- GH Research PLC Trial Data Accepted at ACNP Meeting — 6-K · Oct 17, 2025
- GH Research Presents GH001-TRD-201 Trial Data at ECNP Meeting — 6-K · Oct 14, 2025
- GH Research to Present Clinical Trial Data at ECNP Meeting — 6-K · Oct 10, 2025
- GH Research to Present at ECNP Meeting — 6-K · Oct 9, 2025
- GH Research to Present at TD Cowen Neuropsychiatry Summit — 6-K · Sep 12, 2025
- GH Research to Present Bipolar Trial Data at ISBD Meeting — 6-K · Sep 9, 2025
- GH Research to Present at Cantor Global Healthcare Conference — 6-K · Aug 29, 2025
- GH Research PLC Files 6-K with Financial Updates — 6-K · Aug 7, 2025
- GH Research PLC Annual Meeting: All Resolutions Passed — 6-K · Aug 1, 2025
- Gh Research PLC 20-F/A Filing — 20-F/A · Jul 29, 2025
- GH Research PLC Announces Pivotal Program Plans — 6-K · Jul 23, 2025
- GH Research PLC Responds to FDA Clinical Hold for GH001 — 6-K · Jun 20, 2025
- GH Research PLC Schedules Annual General Meeting for July 31 — 6-K · Jun 18, 2025
- GH Research to Participate in Neuro Perspectives Conference — 6-K · Jun 13, 2025
- GH Research to Present at ASCP Annual Meeting — 6-K · May 27, 2025
- GH Research to Present at ASCP Annual Meeting — 6-K · May 21, 2025
- GH Research PLC Accepted to ASCP Annual Meeting — 6-K · May 15, 2025
- GH Research PLC Files Q1 2025 6-K Report — 6-K · May 8, 2025
- GH Research PLC Files 2024 Annual Report — 20-F · Feb 27, 2025
- GH Research PLC Completes Share Offering — 6-K · Feb 6, 2025
- GH Research Prices $150M Public Offering — 6-K · Feb 5, 2025
- GH Research PLC's GH001 Meets Primary Endpoint in TRD Trial — 6-K · Feb 3, 2025
- GH Research Plans Public Share Offering — 6-K · Feb 3, 2025
- GH Research PLC Files 6-K, Updates GH001 Trial — 6-K · Jan 31, 2025
- GH Research PLC's GH001 Meets Phase 2a Endpoints, FDA Hold Addressed — 6-K · Jan 10, 2025